Breast cancer incidence rates among Native American women are notably lower compared to their white counterparts, yet paradoxically, their mortality rates remain disproportionately high and stagnant over time. This paradox underscores a crucial gap in existing cancer research databases, such as The Cancer Genome Atlas (TCGA), wherein Native American representation is virtually nonexistent—of over a thousand breast cancer cases profiled, only one patient is categorized as Native American. Consequently, current diagnostic and treatment modalities for breast cancer have been developed predominantly based on data from non-Native populations, potentially obscuring population-specific disease dynamics and therapeutic efficacy.

Jun Li, the corresponding author and a professor in the Department of Applied and Computational Mathematics and Statistics at Notre Dame, emphasized the significance of this void in cancer research. “Our study marks a pivotal step in investigating the unique tumor biology in Native American women, an effort that is long overdue,” Li stated. By meticulously comparing 17 breast cancer tumor samples from Native American patients against nearly 700 samples from white women obtained from TCGA, the research team performed an exhaustive molecular profiling that spanned mutational landscapes, gene expression programs, and epigenetic markers.

One of the most striking revelations from this detailed analysis pertained to the immune landscape of the tumors. Tumors from Native American patients exhibited distinct mutational patterns in immune-related genes—a subset of which were exclusively mutated in these patients—implying alterations in how their tumors might evade immune surveillance. This phenomenon of immuno-evasion, a hallmark of cancer progression and therapy resistance, could hold profound implications for immunotherapy approaches tailored for Native American women. Furthermore, the study identified differential mutational burdens in genes responsible for DNA damage repair mechanisms, suggesting variations in genomic stability that may influence therapeutic sensitivity.

Li explained, “We uncovered consistent and pervasive differences across multiple molecular strata. Several critical immune-regulatory genes exhibited higher mutation frequencies in Native American tumor samples compared to those from white patients.” These findings hint at fundamentally different tumor-host immune interactions and raise important questions about the generalizability of immunotherapeutic regimens developed largely with data from other populations. The study underscores the hypothesis that molecular heterogeneity at the population level might translate into differential clinical responses, a concept that has broad implications for precision oncology.

While the current research is exploratory and hypothesis-generating rather than definitive in altering clinical guidelines, it serves as an essential platform for directing future investigations into diverse biological contributors to cancer disparities. Genetic predispositions, environmental exposures, and socioeconomic factors likely interplay in shaping outcomes for Native American breast cancer patients; dissecting these multifactorial influences remains a paramount challenge in the field.

This pioneering investigation is part of a broader initiative by Notre Dame’s Harper Cancer Research Institute, dedicated to expanding biospecimen collections from populations historically marginalized in cancer research. By systematically augmenting tissue repositories with samples from underrepresented groups, including Native American, Panamanian, and Kenyan women, the program aims to enrich the genomic and transcriptomic datasets that underpin cancer biology studies. This initiative not only hopes to fill critical knowledge gaps but also aspires to foster equity in cancer care through more inclusive science.

Sharon Stack, Kleiderer-Pezold Professor of Biochemistry and Director of the Harper Cancer Research Institute, highlighted the impetus behind this research thrust. “While social determinants indisputably impact cancer disparities, our mission is to elucidate whether there are underlying molecular and cellular differences contributing to divergent cancer incidences and outcomes,” she explained. The integration of molecular findings with social and environmental contexts represents a frontier for holistic cancer research.

The biosamples collected through this program undergo custodianship at the Harper Cancer Research Institute’s biosample repository. This repository, which supports tissue banking and distribution services, is a critical resource facilitating collaborative research efforts across South Bend and beyond, enabling scientists and clinicians to access diverse tumor specimens that reflect real-world population heterogeneity.

Jun Li further remarked, “Studying previously overlooked populations frequently uncovers biological insights that challenge prevailing assumptions and enrich our comprehension of cancer.” By capturing the invisible intricacies of tumor biology in Native American women, this research paves the way for more nuanced and effective cancer interventions that transcend one-size-fits-all paradigms.

The study’s lead author, graduate student Fangfang Guo, worked under Li’s guidance to undertake the extensive computational and molecular analyses central to this breakthrough. Co-authorship by Laurie Littlepage, Campbell Family Associate Professor of Cancer Research at Notre Dame, added multidisciplinary expertise to the project, reinforcing the integrative nature of contemporary cancer research.

Funding for this landmark study was provided by the Ryan Gee Excellence Fund for Cancer Research, with additional support from the National Cancer Institute and the Department of Defense Breast Cancer Research Program Breakthrough Award. These investments reflect growing recognition of the critical need to address health disparities through targeted scientific inquiry.

This transformative research underscores a pivotal paradigm shift in oncology: precision medicine must be inclusive medicine. Uncovering the molecular determinants of breast cancer in Native American women is not merely an academic exercise but a vital step toward therapeutic innovation and health equity. As cancer biology continues to be redefined by genomics and advanced bioinformatics, integrating diverse population data will be essential to realizing the full promise of personalized cancer care for all.

Subject of Research: Breast cancer molecular profiling in Native American women revealing distinct genomic and transcriptomic features.

Article Title: Molecular profiling of breast cancer in native American women reveals distinct genomic and transcriptomic features

News Publication Date: 17-Mar-2026

Web References:

• npj Precision Oncology article: https://www.nature.com/articles/s41698-026-01373-6
• The Cancer Genome Atlas: https://www.cancer.gov/ccg/research/genome-sequencing/tcga
• Harper Cancer Research Institute: https://harpercancer.nd.edu/

References:
10.1038/s41698-026-01373-6

Image Credits: Image by Jeff Johnson from the Stack laboratory at Notre Dame showing nuclear localization of NOTCH4, indicative of active Notch signaling associated with cancer stem cells and therapy resistance.

Keywords: Breast cancer, Racial differences, Cancer genomics, Cancer genetics, Immunotherapy, Molecular profiling, Health disparities, Native American women, Tumor biology, DNA damage repair

At the core of this study lies a novel analytical framework tailored to unravel the cellular diversity within breast tumors. Tumors are not monolithic entities; rather, they consist of a mosaic of genetically and phenotypically diverse cancer cell populations coexisting with various microenvironmental components. Recognizing this complexity, the researchers employed single-cell transcriptomics to evaluate three clinically significant breast cancer subtypes: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative (TN). These subtypes differ markedly in their molecular characteristics, clinical outcomes, and responses to therapy, underscoring the need for precision in their molecular characterization.

The methodological innovation of this study involves a multidimensional scoring system, integrating metrics such as copy number alterations (CNAs), entropy, transcriptomic heterogeneity, and protein-protein interaction network (PPIN) activities. CNA analysis at single-cell resolution aids in detecting genomic instabilities that drive tumor evolution. In parallel, entropy measurements quantify the randomness or disorder within the transcriptomic profiles, serving as a proxy for cellular plasticity and phenotypic variation. PPIN activity scores further refine the analysis by mapping functional protein interactions that underscore critical biological pathways associated with oncogenesis and tumor dynamics.

Intriguingly, the researchers observed that entropy and PPIN activity linked to the cell cycle were adept at discriminating clusters of cells exhibiting heightened mitotic activity, a hallmark of aggressive tumor phenotypes. This finding is particularly salient in the context of triple-negative breast cancer, which often features high proliferative indices and poor prognosis. The CNA landscape was also markedly distinct across subtypes, indicating subtype-specific patterns of genomic instability. These disparities in CNA profiles contribute to the molecular heterogeneity that complicates therapeutic targeting.

Moreover, the positive correlations elucidated between CNA scores, entropy, and PPIN activities associated with not only the cell cycle but also basal and mesenchymal cellular phenotypes point to a comprehensive interplay of genetic alterations and dynamic molecular networks in driving tumor heterogeneity. Basal and mesenchymal traits often confer increased mobility and invasiveness to cancer cells, which correlate with metastatic potential. This insight provides a mechanistic framework to better understand how intratumoral diversity fosters aggressive disease behaviors.

The utility of this integrative scoring framework transcends mere classification. By enabling granular characterization of individual tumor cells, the approach captures the nuances of intra- and intertumoral heterogeneity, which are pivotal determinants of tumor evolution and therapeutic resistance. Such a high-resolution lens is crucial for the identification of subpopulations of cancer cells that may evade treatment or serve as reservoirs for relapse. Consequently, this methodology opens avenues for the development of more sophisticated diagnostic tools and personalized treatment strategies.

The application of Uniform Manifold Approximation and Projection (UMAP) visualization further enhances interpretability by projecting high-dimensional single-cell data into comprehensible two-dimensional maps. In these UMAP plots, cancer subtypes—ER+, HER2+, and TN—cluster distinctly yet exhibit varying degrees of overlap, visually reinforcing insights gleaned from quantitative analyses. Color-coded representations indicate sample-specific cellular distributions, allowing for a nuanced appreciation of tumor heterogeneity in spatial contexts.

The implications of this research are far-reaching. By refining the understanding of molecular heterogeneity at the single-cell level, it challenges the prevailing paradigms that rely heavily on bulk tissue analyses or limited marker panels. The findings advocate for the integration of genomic instability metrics with functional network activity profiling to craft multidimensional portraits of tumor biology. This comprehensive depiction is a prerequisite for identifying novel biomarkers and therapeutic targets that can effectively address the multifactorial nature of breast cancer.

In addition to elucidating tumor biology, the study’s quantitative framework offers practical advantages in the clinical realm. It provides a scalable and adaptable computational pipeline that can be applied to diverse single-cell datasets. This flexibility is instrumental in accelerating translational research, enabling rapid hypothesis testing and refinement of therapeutic interventions tailored to the heterogeneity of individual patients’ tumors.

Furthermore, the study underscores the critical role of cell cycle-related pathways in shaping tumor aggressiveness and heterogeneity. The correlation between PPIN activity related to cell division machinery and malignancy heightens the importance of targeting proliferative signaling circuits. Therapeutic strategies aimed at disrupting these networks may attenuate tumor growth and reduce the emergence of resistant clones, thereby improving patient outcomes.

A salient aspect of this research is its contribution to unraveling the enigmatic triple-negative breast cancer subtype. This subtype, characterized by the absence of ER, PR, and HER2 expression, lacks targeted therapies and is associated with poor prognosis. The quantitative insights offered by the integrated analysis of CNAs, entropy, and PPIN activities illuminate potential biological vulnerabilities unique to TN tumors. Identifying these vulnerabilities is indispensable for devising effective therapeutic strategies against this challenging subtype.

In sum, this pioneering investigation leverages the granularity of single-cell RNA sequencing combined with sophisticated computational analyses to dissect tumor heterogeneity in breast cancer subtypes. The integration of genomic instability metrics, transcriptomic disorder, and functional network activity creates a powerful lens through which the multifaceted nature of tumors can be understood. Through its detailed quantitative framework and rich biological insights, the study sets a new benchmark for cancer research aimed at precision medicine.

The prospective impact of this work is profound, offering a roadmap for exploiting tumor heterogeneity to improve diagnosis, prognosis, and treatment. As single-cell technologies continue to evolve, combining these data with functional and clinical outcomes will be critical to fully realize the promise of personalized oncology. This study not only extends the frontier of breast cancer biology but also epitomizes the transformative potential of single-cell multi-omics in the broader landscape of cancer research.

Subject of Research: Breast cancer tumor heterogeneity analyzed through single-cell RNA sequencing.

Article Title: Unraveling Tumor Heterogeneity: Quantitative Insights from Single-cell RNA Sequencing Analysis in Breast Cancer Subtypes

News Publication Date: 25-Apr-2025

Web References:

• DOI Link
• Gene Expression Journal

Image Credits: Credit: Diambra, Daniela Senra

Keywords: Breast cancer, tumor heterogeneity, single-cell RNA sequencing, copy number alterations, entropy, protein-protein interaction networks, ER-positive, HER2-positive, triple-negative, cell cycle, transcriptomic heterogeneity, molecular oncology